ͽÄêɽ -¾ÜºÙ¾ðÊó-
·ï̾ | BS ʬ²Ê²ñ |
³«»ÏÆü»þ | 2012ǯ 11·î 27Æü (²ÐÍËÆü) 10»þ40ʬ (GMT+09:00) |
½ªÎ»Æü»þ | 2012ǯ 11·î 27Æü (²ÐÍËÆü) 12»þ10ʬ (GMT+09:00) |
¾ì½ê | ²¼µ»²¾È¤Î»ö |
¾ÜºÙ | ¡Ú¥°¥ë¡¼¥×1¡Û¼Â¸³¡¦À¤ÏÀÄ´ºº¡¦Åý·×ʬÀÏ ¾ì½ê¡§6¹æ´Û313-2¶µ¼¼ ÆâÍÆ¡§¡Ö¼Â¸³¼Â»Ü¤Ë¸þ¤±¤¿Ï䷹礤¤ò¹Ô¤¦¡× ¡Ú¥°¥ë¡¼¥×2¡Û»ý³²Äǽ¤ÊÀ©ÅÙÀ߷פȵ¬ÈÏŪɾ²Á ¾ì½ê¡§6¹æ´Û313¶µ¼¼ ÆâÍÆ¡§ ¡Ö²¬ÌîȬÂåÀèÀ¸¡ÊƱ»Ö¼ÒÂç³Ø¡Ë¤Ë¤è¤ë¹ÖµÁ¡ÖÆüËÜ·³¡Ö°Ö°ÂÉØ¡×ÌäÂê¤ÈÀ¯¼£³Ø¤Îº£¡×¡× ¡Ú¥°¥ë¡¼¥×3¡Û¡§¹ñºÝÀ¯¼£·ÐºÑ¥â¥Ç¥ëʬÀÏ¡¢ ¾ì½ê¡§1¹æ´Û401¶µ¼¼ ÆâÍÆ¡§ ¸¦µæ¥»¥ß¥Ê¡¼ Êó¹ð¼Ô¡§ÈÓÄÍÉÒ¹¸»á¡ÊÅìµþÂç³Ø¡Ë Êó¹ð¥¿¥¤¥È¥ë¡§Physician Agency and Adoption of Generic Pharmaceuticals ³µÍס§ I examine physician agency in health care services in the context of the choice between brand-name and generic pharmaceuticals. I examine micro-panel data from Japan, where physicians can legally make profits by prescribing and dispensing drugs. The results indicate that physicians often fail to internalize patient costs, explaining why cheaper generics are infrequently adopted. Doctors respond to markup differentials between the two versions, indicating another agency problem.¡¡However, generics¡Ç markup advantages are shortlived, which limits their impact on increasing generic adoption. Additionally, state dependence and heterogeneous doctor preferences affected generics¡Ç adoption. Policy makers can target these factors to improve static efficiency. ¡Ú¥°¥ë¡¼¥×4¡Û¡§À©ÅÙ¤ÎÀ¸À®¤ÈÀ߷פοôÍýŪ´ðÁÃÉÕ¤± ¾ì½ê¡§9¹æ´Û318¶µ¼¼ ÆâÍÆ¡§¡Ê¹ÖµÁ¡ËÀ¯¼£·ÐºÑ³Ø¤Ø¤Î¥²¡¼¥àÏÀŪ¥¢¥×¥í¡¼¥Á |
¥«¥Æ¥´¥ê¡¼ | À¯¼£·ÐºÑ³Ø´ðÁÃ¥»¥ß¥Ê¡¼¡¦¥é¥ó¥Á¥¿¥¤¥à¥»¥ß¥Ê¡¼ |